These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 32055713)

  • 1. Molecular dynamics simulation study of AG10 and tafamidis binding to the Val122Ile transthyretin variant.
    Morris KF; Geoghegan RM; Palmer EE; George M; Fang Y
    Biochem Biophys Rep; 2020 Mar; 21():100721. PubMed ID: 32055713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conventional Molecular Dynamics and Metadynamics Simulation Studies of the Binding and Unbinding Mechanism of TTR Stabilizers AG10 and Tafamidis.
    Zhou S; Ge S; Zhang W; Zhang Q; Yuan S; Lo GV; Dou Y
    ACS Chem Neurosci; 2020 Oct; 11(19):3025-3035. PubMed ID: 32915538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conserved water mediated H-bonding dynamics of Ser117 and Thr119 residues in human transthyretin-thyroxin complexation: inhibitor modeling study through docking and molecular dynamics simulation.
    Banerjee A; Bairagya HR; Mukhopadhyay BP; Nandi TK; Mishra DK
    J Mol Graph Model; 2013 Jul; 44():70-80. PubMed ID: 23732306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy.
    Judge DP; Heitner SB; Falk RH; Maurer MS; Shah SJ; Witteles RM; Grogan M; Selby VN; Jacoby D; Hanna M; Nativi-Nicolau J; Patel J; Rao S; Sinha U; Turtle CW; Fox JC
    J Am Coll Cardiol; 2019 Jul; 74(3):285-295. PubMed ID: 30885685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy.
    Sultan MB; Gundapaneni B; Schumacher J; Schwartz JH
    Clin Med Insights Cardiol; 2017; 11():1179546817730322. PubMed ID: 28951660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure of the Val122Ile variant transthyretin - a cardiomyopathic mutant.
    Damas AM; Ribeiro S; Lamzin VS; Palha JA; Saraiva MJ
    Acta Crystallogr D Biol Crystallogr; 1996 Sep; 52(Pt 5):966-72. PubMed ID: 15299606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel identification approach for discovery of 5-HydroxyTriptamine 2A antagonists: combination of 2D/3D similarity screening, molecular docking and molecular dynamics.
    Kumar R; Jade D; Gupta D
    J Biomol Struct Dyn; 2019 Mar; 37(4):931-943. PubMed ID: 29468945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.
    Park J; Egolum U; Parker S; Andrews E; Ombengi D; Ling H
    Ann Pharmacother; 2020 May; 54(5):470-477. PubMed ID: 31735059
    [No Abstract]   [Full Text] [Related]  

  • 9. Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.
    Connelly S; Mortenson DE; Choi S; Wilson IA; Powers ET; Kelly JW; Johnson SM
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3441-3449. PubMed ID: 28625364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biophysical characterization and modulation of Transthyretin Ala97Ser.
    Liu YT; Yen YJ; Ricardo F; Chang Y; Wu PH; Huang SJ; Lin KP; Yu TY
    Ann Clin Transl Neurol; 2019 Oct; 6(10):1961-1970. PubMed ID: 31502419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural evidence for asymmetric ligand binding to transthyretin.
    Cianci M; Folli C; Zonta F; Florio P; Berni R; Zanotti G
    Acta Crystallogr D Biol Crystallogr; 2015 Aug; 71(Pt 8):1582-92. PubMed ID: 26249340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis.
    Waddington Cruz M; Benson MD
    Neurol Ther; 2015 Dec; 4(2):61-79. PubMed ID: 26662359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploration of the Misfolding Mechanism of Transthyretin Monomer: Insights from Hybrid-Resolution Simulations and Markov State Model Analysis.
    Zhou S; Cheng J; Yang T; Ma M; Zhang W; Yuan S; Lo GV; Dou Y
    Biomolecules; 2019 Dec; 9(12):. PubMed ID: 31861226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy).
    Cho Y; Baranczak A; Helmke S; Teruya S; Horn EM; Maurer MS; Kelly JW
    Amyloid; 2015; 22(3):175-80. PubMed ID: 26193961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural insights into pharmacophore-assisted in silico identification of protein-protein interaction inhibitors for inhibition of human toll-like receptor 4 - myeloid differentiation factor-2 (hTLR4-MD-2) complex.
    Mishra V; Pathak C
    J Biomol Struct Dyn; 2019 May; 37(8):1968-1991. PubMed ID: 29842849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conformational Equilibria of Multimodal Chromatography Ligands in Water and Bound to Protein Surfaces.
    Bilodeau CL; Lau EY; Cramer SM; Garde S
    J Phys Chem B; 2019 Jun; 123(23):4833-4843. PubMed ID: 31117605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the microscopic binding mechanism of hydroxylated and sulfated polybrominated diphenyl ethers with transthyretin by molecular docking, molecular dynamics simulations and binding free energy calculations.
    Cao H; Sun Y; Wang L; Zhao C; Fu J; Zhang A
    Mol Biosyst; 2017 Mar; 13(4):736-749. PubMed ID: 28217795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long dynamics simulations of proteins using atomistic force fields and a continuum representation of solvent effects: calculation of structural and dynamic properties.
    Li X; Hassan SA; Mehler EL
    Proteins; 2005 Aug; 60(3):464-84. PubMed ID: 15959866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tafamidis, a Noninvasive Therapy for Delaying Transthyretin Familial Amyloid Polyneuropathy: Systematic Review and Meta-Analysis.
    Zhao Y; Xin Y; Song Z; He Z; Hu W
    J Clin Neurol; 2019 Jan; 15(1):108-115. PubMed ID: 30618225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.